España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Innate Pharma
IPHA
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$2.09
-0.17
-7.52%
At Close: -
$2.29
0.2
9.57%
After Hours: Jul 23, 5:44 AM EDT
15 minutes delayed
Get Report
Comment
Innate Pharma (IPHA) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Innate Pharma (NASDAQ:IPHA) Stock
Innate Pharma Stock (NASDAQ: IPHA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, June 17, 2024
Innate Pharma And Sanofi's Blood Cancer Treat...
Benzinga Newsdesk
Wednesday, June 12, 2024
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Tuesday, June 04, 2024
Innate Pharma Reveals Results From TELLOMAK P...
Benzinga Newsdesk
Wednesday, May 15, 2024
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Innate Pharma's Four Abstracts With Innate's ...
Benzinga Newsdesk
Tuesday, May 14, 2024
Innate Pharma Reported Q1 Revenue Of €6.6M Do...
Benzinga Newsdesk
Monday, April 15, 2024
Innate Pharma Advances Sanofi-Developed NK Ce...
Benzinga Newsdesk
Thursday, April 11, 2024
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Wednesday, April 10, 2024
Innate Pharma Presents Preclinical Efficacy O...
Benzinga Newsdesk
Friday, April 05, 2024
Innate Pharma Says It Filed Its 2023 Universa...
Benzinga Newsdesk
Wednesday, April 03, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Monday, April 01, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Friday, March 22, 2024
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Thursday, March 21, 2024
Earnings Scheduled For March 21, 2024
Benzinga Insights
Innate Pharma FY EPS $(0.10) Up From $(0.75) ...
Benzinga Newsdesk
Monday, March 11, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Wednesday, March 06, 2024
Innate Pharma Announces That It Will Present ...
Benzinga Newsdesk
Innate Pharma's First Patient Dosed In Phase ...
Benzinga Newsdesk
Tuesday, February 06, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Thursday, January 04, 2024
Innate Pharma Announces FDA's Removal Of Part...
Benzinga Newsdesk
Wednesday, December 20, 2023
Innate Pharma Filed For Stock Shelf Of Up To $200M-
Charles Gross
Tuesday, December 19, 2023
Sanofi To Exercise Option To License A New AN...
Benzinga Newsdesk
Monday, December 18, 2023
Innate Pharma CEO Mondher Mahjoubi To Depart ...
Benzinga Newsdesk
Monday, December 11, 2023
Reported On Sunday, Innate Pharma To Present ...
Benzinga Newsdesk
Innate Pharma Shares Efficacy And Safety Phas...
Benzinga Newsdesk
Monday, November 27, 2023
Innate Pharma Announces Virtual Key Opinion L...
Benzinga Newsdesk
Wednesday, November 15, 2023
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Tuesday, November 14, 2023
Innate Pharma Reported First Nine Months FY23...
Benzinga Newsdesk
Friday, November 03, 2023
Innate Pharma To Present New Clinical Data Fo...
Benzinga Newsdesk
Thursday, October 05, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
Vandana Singh
Innate Pharma's Lacutamab IND Trials On Parti...
Benzinga Newsdesk
Friday, September 22, 2023
Innate Pharma To Present Interim Results Of P...
Benzinga Newsdesk
Monday, September 18, 2023
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Thursday, September 14, 2023
Innate Pharma H1 EPS $0.02 Down From $0.09 Yo...
Benzinga Newsdesk
Tuesday, July 11, 2023
Innate Pharma Announced That The First Patien...
Benzinga Newsdesk
Monday, June 26, 2023
Innate Pharma Has Dosed The First Patient In ...
Benzinga Newsdesk
Friday, June 16, 2023
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Innate Pharma Says That Interim Efficacy Resu...
Benzinga Newsdesk
Thursday, June 08, 2023
The FDA Has Granted Fast Track Designation To...
Benzinga Newsdesk
Friday, May 26, 2023
Innate Pharma Highlights Phase 1/2 Safety, Pr...
Benzinga Newsdesk
Wednesday, May 10, 2023
Innate Pharma SA Registers Revenue Of €26.0M ...
Benzinga Newsdesk
Thursday, April 27, 2023
Innate Pharma Establishes A New At-The-Market Program On Nasdaq; Company May Offer And Sell A Total $75M Co. ADS From Time To Time
Happy Mohamed
Wednesday, April 19, 2023
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
David Willey
-
Sponsored
Monday, April 03, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Innate Pharma Has Granted Takeda Exclusive Wo...
Benzinga Newsdesk
Friday, March 24, 2023
HC Wainwright & Co. Reiterates Buy on Innate ...
Benzinga Newsdesk
Thursday, March 23, 2023
Earnings Scheduled For March 23, 2023
Benzinga Insights
Innate Pharma Reports 133.5% Revenue Growth Y...
Benzinga Newsdesk
Tuesday, February 14, 2023
Innate Pharma, Orega Biotech Granted U.S. Patent #11578136: Compositions And Methods For Treating Cancer
Charles Gross
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch